OccuRx Overview

  • Founded
  • 2014
  • Status
  • Private
  • Employees
  • 5
  • Latest Deal Type
  • Seed
  • Latest Deal Amount
  • $5.13M
Latest Deal Amount
  • Investors
  • 3

OccuRx General Information


Developer of therapeutic strategies designed to aid in the treatment of disorders associated with retinal fibrosis. The company's strategies offer proprietary small molecule drugs to address the unmet clinical need for more targeted ocular therapies to enhance visual acuity and prevent vision loss in inflammatory and degenerative eye diseases, enabling healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce inflammation of the neurons in the retina.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Level 9
  • 31 Queen Street
  • Melbourne, Victoria 3000
  • Australia
+61 (03) 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

OccuRx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Seed Round 19-May-2015 $5.13M 00.000 Completed Startup
1. Angel (individual) Completed Startup
To view OccuRx’s complete valuation and funding history, request access »

OccuRx Comparisons

HQ Location
Total Raised
Post Valuation
Last Financing Details
Developer of therapeutic strategies designed to aid in the treatment of disorders associated with retinal fibrosis. The
Melbourne, Australia
5 As of 2021
000000000 00.000


tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitat
0000 000000000
Boston, MA
0 As of 0000
000000000 00000


laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptat
San Francisco, CA
000 As of 0000
0.00 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OccuRx Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aileron Therapeutics Formerly VC-backed Boston, MA 0 00000 000000000 00000
00000000 000000000 Formerly VC-backed San Francisco, CA 000 00000 000000&0 00000
0000000 0000000000 Formerly VC-backed Redwood City, CA 000 00000 000000000 00000
00000000 Private Equity-Backed Carrollton, TX 00 000.00 00 000000 000.00
000000000 00000000 Formerly VC-backed Alpharetta, GA 00 00000 000000000 00000
You’re viewing 5 of 8 competitors. Get the full list »

OccuRx Executive Team (4)

Name Title Board Seat Contact Info
Eric Daniels MD Chief Executive Officer
Ann Hamer Chief Operating Officer
Fay Khong Ph.D Senior Associate, Research & Commercialisation
Darren Kelly Ph.D Founder & Executive Chairman
To view OccuRx’s complete executive team members history, request access »

OccuRx Board Members (3)

Name Representing Role Since
Chris Nave Ph.D Self Board Member 000 0000
Darren Kelly Ph.D OccuRx Founder & Executive Chairman 000 0000
John Kurek Ph.D Self Board Member 000 0000
To view OccuRx’s complete board members history, request access »

OccuRx Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OccuRx Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Brandon Capital Partners Venture Capital Minority 000 0000 000000 0
The Medical Research Commercialisation Fund Venture Capital Minority 000 0000 000000 0
Uniseed Venture Capital Minority 000 0000 000000 0
To view OccuRx’s complete investors history, request access »